Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8)

Clinical and Experimental Immunology

Volumn 158, Issue 2, 2009, Pages 246-256

  Zack, M D ^a   Melton, M A ^a   Stock, J L ^a   Storer, C E ^a   Barve, R A ^a   Minnerly, J C ^a   Weiss, D J ^a   Stejskal, J A ^a   Tortorella, M D ^a   Turk, J R ^b   Shevlin, K M ^a   Malfait, A M ^c  

^a PFIZER INC   (United States)

^b AMGEN INC   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endotoxin shock; Inflammation; Rheumatoid arthritis; Transgenic mice

Indexed keywords

ADAM PROTEIN; ADAM8 PROTEIN; GLUTAMIC ACID; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; INCIDENCE; MACROPHAGE; MALE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; ORGAN WEIGHT; OSTEOLYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; SYNOVITIS; TRANSGENIC MOUSE; WILD TYPE;

ADAM PROTEINS; ANIMALS; ANTIGENS, CD; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CATALYSIS; CELLS, CULTURED; COLLAGEN TYPE II; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GLUTAMIC ACID; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED DBA; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; POINT MUTATION; SEVERITY OF ILLNESS INDEX;

EID: 70349694097     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04009.x     Document Type: Article

References (37)

1. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 : 315 324.
2. Gorman CL, Cope AP. Immune-mediated pathways in chronic inflammatory arthritis. Best Pract Res Clin Rheumatol 2008 22 : 221 238.
3. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008 223 : 7 19.
4. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
5. Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008 67 (Suppl. 3 iii2 25.
6. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol 2003 54 : 101 123.
7. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003 17 : 7 30.
8. Kheradmand F, Werb Z. Shedding light on sheddases: role in growth and development. Bioessays 2002 24 : 8 12.
9. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2009 29 : 258 289.
10. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 1997 41 : 56 62.
11. Gomez-Gaviro M, Dominguez-Luis M, Canchado J et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007 178 : 8053 8063.
12. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007 19 : 289 295.
13. Mandelin J, Li TF, Hukkanen MV et al. Increased expression of a novel osteoclast-stimulating factor, ADAM8, in interface tissue around loosened hip prostheses. J Rheumatol 2003 30 : 2033 2038.
14. Ainola M, Li TF, Mandelin J et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction. Ann Rheum Dis 2009 68 : 427 434.
15. Amour A, Knight CG, English WR et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002 524 : 154 158.
16. Hall T, Leone JW, Wiese JF et al. Autoactivation of human ADAM8: a novel pre-processing step is required for catalytic activity. Biosci Rep 2008.
17. Schlomann U, Wildeboer D, Webster A et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002 277 : 48210 48219.
18. Roach ML, Stock JL, Byrum R, Koller BH, McNeish JD. A new embryonic stem cell line from DBA/1lacJ mice allows genetic modification in a murine model of human inflammation. Exp Cell Res 1995 221 : 520 525.
19. Stanley ER. Murine bone marrow-derived macrophages. Methods Mol Biol 1997 75 : 301 304.
20. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981 154 : 688 700.
21. Bendele AM, Chlipala ES, Scherrer J et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000 43 : 2648 2659.
22. Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J Immunol 2007 179 : 5576 5583.
23. Beare A, Stockinger H, Zola H, Nicholson I. Monoclonal antibodies to human cell surface antigens. Curr Protoc Immunol 2008 Appendix 4 : 4A.
24. Nadel JA. Biology of mast cell tryptase and chymase. Ann NY Acad Sci 1991 629 : 319 331.
25. Paul WE. Fundamental immunology. Philadelphia, PA : Lippincott-Raven, 1999 : 1051 1066.
26. Moss ML, Rasmussen FH. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 2007 366 : 144 148.
27. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007 98 : 621 628.
28. Kelly K, Hutchinson G, Nebenius-Oosthuizen D et al. ADAM8: expression analysis and targeted deletion in mice. Dev Dyn 2005 232 : 221 231.
29. Hill RJ, Dabbagh K, Phippard D et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008 327 : 610 619.
30. Ibrahim SM, Yu X. Dissecting the genetic basis of rheumatoid arthritis in mouse models. Curr Pharm Des 2006 12 : 3753 3759.
31. Caccese RG, Zimmerman JL, Carlson RP. Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice. Mediators Inflamm 1992 1 : 273 279.
32. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996 39 : 797 809.
33. Choi SJ, Han JH, Roodman GD. ADAM8: a novel osteoclast stimulating factor. J Bone Miner Res 2001 16 : 814 822.
34. Rao H, Lu G, Kajiya H et al. a novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 2006 21 : 1657 1665.
35. Naus S, Reipschlager S, Wildeboer D et al. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem 2006 387 : 337 346.
36. Xanthoulea S, Pasparakis M, Kousteni S et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004 200 : 367 376.
37. Mihara K, Almansa C, Smeets RL et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol 2008 154 : 153 164.